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Chronic Hepatitis C Virus (HCV) infection can result in the
development of liver cirrhosis and is a major cause for the
development of Hepatocellular Carcinoma (HCC) in the
United States. With the initiation of HCV treatment in 2014
by Direct Acting Antivirals (DAA) which are highly
effective in clearing HCV infections and safe for
administration to patients with cirrhosis, it is anticipated
that the epidemiology of HCC will be shifting.
Unfortunately, viral elimination may occur in a setting
where the HCC development pathway has already begun.
Our objective was to determine whether achieving a
sustained virologic response (SVR) in patients with
cirrhosis prior to diagnosis of hepatocellular carcinoma
(HCC) improved outcomes in our predominately
African American population.
We reviewed the medical records of 96 HCV patients
diagnosed with HCC between 2015 and 2019 (Figure1).
Demographics, tumor size, treatment profiles, and outcomes
following diagnosis were determined. Primary outcomes were
defined as either alive, transplant or death/hospice. Tumor size
was measured as non-small (> 5cm or multiple tumors) or small
(< 5cm). The study was approved by the WSU IRB and data
analysis performed using the SAS-JMP software.
• Most patients with HCC in this study did not receive
treatment for their HCV prior to HCC diagnosis, despite the
introduction of treatment in 2014.
• Prior treatment of HCV in patients with cirrhosis leads to
better outcomes than with no treatment. Even though tumor
size is known to correlate with survival, tumor size at
diagnosis was similar between treated and not treated patients.
The reason for this discrepancy is not known.
• Since many of our cirrhotic patients treated for HCV with
DAA have not yet developed HCC or have not yet reached a
final outcomes, we will need to continue to expand and
monitor our HCC patient population into the future analysis.
Figure 4: Survival  (alive as compared to Death/Hospice)) was plotted as a function of time in 
months. Patients who were treated and achieved a sustained viral response prior to diagnosis of HCC are 
compared to patients with HCV who were not treated prior to diagnosis of their HCC.
Figure 2: Patient outcomes 
comparing treated and not 
treated patients. The red bar 
is patients who are alive, 
and the green bar the 
patients who are dead or in 
hospice . The blue bar is the 
patient who received a 
transplant. 
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Figure 1   Distribution of patients by date of diagnosis of their HCC and 
whether they were treated for HCV prior to their diagnosis  All of treated 
patients achieved viral clearance (Sustained Virus Response; SVR)
Only 17 (18%)  of the 96 patients with HCV who developed 
HCC, were treated for their HCV prior to diagnosis (figure 1). 
There was no significant difference in the gender, race, and 
age of treated or non-treated patients.
There was no significant difference in tumor size between HCV 
treated or not treated patients (29% compared to 25%, p = 
0.7297; Figure 3).
Patients who were treated for their HCV prior to 
diagnosis were more likely to be alive in 2020 than% 
patients who were not treated (47% compared to 19& p = 
0.0078; figure 2). 
Time to death or hospice was shorter for patients who were 
not treated as compared to patients who were treated. 
Figure 3: Tumor size at 
diagnosis and treatment 
status.  Patients who were 
treated were not more 
likely to be diagnosed with 
a small tumor as compared 
to patients who were not 
treated for their HCV. 
Most patients were not 
identified under a 
surveillance protocol
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Most treated patients (15) were diagnosed within three years
of treatment. Two patients with the longest time between
treatment and HCC diagnosis (12 and 14 years) were treated
with Interferon and Ribavirin and had minimal cirrhosis at
the time of treatment.
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